Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.

Antiviral research - 1 Dec 2016

Boglione Lucio, Cusato Jessica, Cariti Giuseppe, Di Perri Giovanni, D'Avolio Antonio

Abstract excerpt

Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-negative are pegylated interferon alfa-2a (PEG-IFN) for 48 weeks or nucleos(t)ide analogues (NAs). The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to DNA, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to Interferon-alpha

Share to Polyethylene Glycols

Source

Identifiers

PMID: 27793564
DOI: 10.1016/j.antiviral.2016.10.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.PMID 27793564Read ↗

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.Semantic proximity Read ↗

Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis.Semantic proximity Read ↗

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.Semantic proximity Read ↗

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.Semantic proximity Read ↗

Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.Semantic proximity Read ↗

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.Semantic proximity Read ↗

Response predictors to treatment with pegylated interferon in chronic hepatitis B.Semantic proximity Read ↗

Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.Semantic proximity Read ↗

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.Semantic proximity Read ↗

Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.Semantic proximity Read ↗

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.Semantic proximity Read ↗

The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.